Novalis Biotech Announces the Closing of a €25 Million Biotech Acceleration Fund

Novalis Biotech, an early-stage venture capital investor in healthcare-related technology, announced today the completion of its €25 million second fund, the Novalis Biotech Acceleration Fund. The fundraising has included both new and returning investors. The second fund's investor base comprises institutional investors, including Participate Maatschappij Vlaanderen (PMV), family offices, and high-net-worth individuals (HNWIs).

The Biotech Acceleration Fund will continue to invest in start-up and scale-up companies that use "enabling technologies" to improve healthcare. Genomic and bioinformatics technologies, drug research and manufacturing tools, diagnostics, and personalized medicine are examples. The funds will be divided between early-stage incubation initiatives and late-stage acceleration programs. Grapheal and RheaVita have already made investments in the enabling technologies they are developing. Novalis will continue to use its strong network in the Benelux area and intends to expand its investments throughout Western Europe and the United States.

Novalis invests early and focuses on capital-light ideas where modest investments can generate substantial value using software, intellectual property, tools, and other enabling technologies that can transform healthcare. Novalis has a strong track record of turning ideas into profitable businesses by using extensive networks.

Novalis Fund 1 was established in September 2018 with a total capitalization of €4 million, which was invested in eight companies, the majority of which were located in the Benelux region. BioLizard, Cergentis, Enzyre, Epify, Fertiga, myNEO, and OHMX.bio are among them. A first exit occurred when doc.ai, a US portfolio company, was acquired by Sharecare as part of an IPO.

About Novalis Biotech Acceleration
Novalis Biotech is an early-stage venture capital investor in healthcare-revolutionizing technologies. The company's main competence is digitalization in the life sciences, focusing on capital-light "enabling technologies" such as bioinformatics, artificial intelligence, genomics, personalized medicine, research or manufacturing tools, and diagnostics.